The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis

(2014) M. A. Nowell et al.   JOURNAL OF IMMUNOLOGY

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+T cells

(2009) Oliver Dienz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

(2009) Jean-Michel Dayer et al.   RHEUMATOLOGY

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion

(2008) C. Chizzolini et al.   BLOOD

Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus

(2008) Yih-Hsin Chang et al.   CLINICAL BIOCHEMISTRY

Th17 cells: a new fate for differentiating helper T cells

(2008) Zhi Chen et al.   IMMUNOLOGIC RESEARCH

Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways

(2008) Fumio Yoshitake et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

(2008) Gillian Murphy et al.   Nature clinical practice. Rheumatology

Systemic inflammation as a risk factor for atherothrombosis

(2007) S. I. van Leuven et al.   RHEUMATOLOGY